Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response…
Pfizer Inc. and BioNTech SE announced additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The study results…
Read More...
Read More...
